IOVA
insider transactionsIOVANCE BIOTHERAPEUTICS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
90.3K sh
Own New
-
Grant·A
Director
$0
90.3K sh
Own New
-
Grant·A
Chief Regulatory Officer
$0
15.0K sh
Own New
-
Grant·A
Director
$0
180.6K sh
Own New
-
Grant·A
Director
$0
90.3K sh
Own New
-
Exercise·M
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
15.6K sh
Own +17%
-
Other·F
Frederick G Vogt KEY
Interim CEO & General Counsel
$28.1K
6.6K sh · $4.23
Own -1%
-
Exercise·M
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
15.6K sh
Own +3%
-
Exercise·M
Chief Regulatory Officer
$0
9.8K sh
Own +17%
-
Other·F
Chief Regulatory Officer
$16.3K
3.8K sh · $4.23
Own -2%
-
Exercise·M
Chief Regulatory Officer
$0
9.8K sh
Own +4%
-
Exercise·M
Chief Medical Officer
$0
7.8K sh
Own +17%
-
Other·F
Chief Medical Officer
$16.8K
4.0K sh · $4.23
Own -3%
-
Exercise·M
Chief Medical Officer
$0
7.8K sh
Own +6%
-
Exercise·M
Chief Operating Officer
$0
7.8K sh
Own +17%
-
Other·F
Chief Operating Officer
$16.8K
4.0K sh · $4.23
Own -3%
-
Exercise·M
Chief Operating Officer
$0
7.8K sh
Own +6%
-
Exercise·M
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
41.7K sh
Own +50%
-
Other·F
Frederick G Vogt KEY
Interim CEO & General Counsel
$70.1K
17.7K sh · $3.96
Own -3%
-
Exercise·M
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
41.7K sh
Own +8%
-
Exercise·M
Chief Regulatory Officer
$0
5.5K sh
Own +50%
-
Other·F
Chief Regulatory Officer
$9.9K
2.5K sh · $3.96
Own -1%
-
Exercise·M
Chief Regulatory Officer
$0
5.5K sh
Own +2%
-
Exercise·M
Chief Medical Officer
$0
8.8K sh
Own +50%
-
Other·F
Chief Medical Officer
$17.7K
4.5K sh · $3.96
Own -3%
-
Exercise·M
Chief Medical Officer
$0
8.8K sh
Own +7%
-
Exercise·M
Chief Operating Officer
$0
8.8K sh
Own +50%
-
Other·F
Chief Operating Officer
$17.7K
4.5K sh · $3.96
Own -3%
-
Exercise·M
Chief Operating Officer
$0
8.8K sh
Own +7%
-
Grant·A
Director
$0
10.5K sh
Own New
-
Exercise·M
Chief Commercial Officer
$0
10.0K sh
Own +17%
-
Other·F
Chief Commercial Officer
$9.0K
2.4K sh · $3.70
Own -2%
-
Exercise·M
Chief Commercial Officer
$0
10.0K sh
Own +7%
-
Grant·A
Corleen M. Roche KEY
Chief Financial Officer
$0
132.2K sh
Own New
-
Grant·A
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
235.0K sh
Own New
-
Grant·A
Chief Regulatory Officer
$0
117.5K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
132.2K sh
Own New
-
Grant·A
Chief Medical Officer
$0
58.8K sh
Own New
-
Grant·A
Chief Operating Officer
$0
117.5K sh
Own New
-
Grant·A
Iain D. Dukes KEY
Chief Executive Officer
$0
231.3K sh
Own New
-
Exercise·M
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
62.5K sh
Own +100%
-
Other·F
Frederick G Vogt KEY
Interim CEO & General Counsel
$122.5K
26.8K sh · $4.58
Own -5%
-
Exercise·M
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
62.5K sh
Own +13%
-
Exercise·M
Chief Regulatory Officer
$0
39.1K sh
Own +100%
-
Other·F
Chief Regulatory Officer
$84.1K
18.4K sh · $4.58
Own -7%
-
Exercise·M
Chief Regulatory Officer
$0
39.1K sh
Own +18%
-
Exercise·M
Chief Medical Officer
$0
31.2K sh
Own +100%
-
Other·F
Chief Medical Officer
$75.7K
16.5K sh · $4.58
Own -11%
-
Exercise·M
Chief Medical Officer
$0
31.2K sh
Own +27%
-
Exercise·M
Chief Operating Officer
$0
31.2K sh
Own +100%
-
Other·F
Chief Operating Officer
$76.2K
16.6K sh · $4.58
Own -12%
-
Exercise·M
Chief Operating Officer
$0
31.2K sh
Own +28%
-
Exercise·M
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
10.4K sh
Own New
-
Exercise·M
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
41.7K sh
Own +33%
-
Other·F
Frederick G Vogt KEY
Interim CEO & General Counsel
$86.4K
22.8K sh · $3.79
Own -4%
-
Exercise·M
Frederick G Vogt KEY
Interim CEO & General Counsel
$0
52.1K sh
Own +11%
-
Exercise·M
Chief Regulatory Officer
$0
5.5K sh
Own +33%
-
Other·F
Chief Regulatory Officer
$10.6K
2.8K sh · $3.79
Own -1%
-
Exercise·M
Chief Regulatory Officer
$0
5.5K sh
Own +3%
-
Exercise·M
Chief Medical Officer
$0
3.9K sh
Own New
-
Exercise·M
Chief Medical Officer
$0
8.8K sh
Own +33%
-
Other·F
Chief Medical Officer
$27.0K
7.1K sh · $3.79
Own -6%
-
Exercise·M
Chief Medical Officer
$0
12.7K sh
Own +11%
-
Exercise·M
Chief Operating Officer
$0
3.5K sh
Own New
-
Exercise·M
Chief Operating Officer
$0
8.8K sh
Own +33%
-
Other·F
Chief Operating Officer
$26.2K
6.9K sh · $3.79
Own -6%
-
Exercise·M
Chief Operating Officer
$0
12.3K sh
Own +12%
-
Exercise·M
Chief Commercial Officer
$0
150.0K sh
Own New
-
Other·F
Chief Commercial Officer
$129.1K
34.2K sh · $3.78
Own -20%
-
Exercise·M
Chief Commercial Officer
$0
120.0K sh
Own +224%
-
Exercise·M
Chief Commercial Officer
$0
40.0K sh
Own +100%
-
Other·F
Chief Commercial Officer
$42.8K
16.4K sh · $2.60
Own -24%
-
Exercise·M
Chief Commercial Officer
$0
40.0K sh
Own +133%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Michael Weiser | Grant A | 90.3K | $0 |
| Jun 16, 2026 | Ryan D Maynard | Grant A | 90.3K | $0 |
| Jun 16, 2026 | Raj K. Puri | Grant A | 15.0K | $0 |
| Jun 16, 2026 | Iain D. Dukes | Grant A | 180.6K | $0 |
| Jun 16, 2026 | Athena Countouriotis | Grant A | 90.3K | $0 |
| Jun 5, 2026 | Frederick G Vogt KEY | Exercise M | 15.6K | $0 |
| Jun 5, 2026 | Frederick G Vogt KEY | Other F | 6.6K | $28.1K |
| Jun 5, 2026 | Frederick G Vogt KEY | Exercise M | 15.6K | $0 |
| Jun 5, 2026 | Raj K. Puri | Exercise M | 9.8K | $0 |
| Jun 5, 2026 | Raj K. Puri | Other F | 3.8K | $16.3K |
| Jun 5, 2026 | Raj K. Puri | Exercise M | 9.8K | $0 |
| Jun 5, 2026 | Finckenstein Friedrich Graf | Exercise M | 7.8K | $0 |
| Jun 5, 2026 | Finckenstein Friedrich Graf | Other F | 4.0K | $16.8K |
| Jun 5, 2026 | Finckenstein Friedrich Graf | Exercise M | 7.8K | $0 |
| Jun 5, 2026 | Igor Bilinsky | Exercise M | 7.8K | $0 |
| Jun 5, 2026 | Igor Bilinsky | Other F | 4.0K | $16.8K |
| Jun 5, 2026 | Igor Bilinsky | Exercise M | 7.8K | $0 |
| Jun 1, 2026 | Frederick G Vogt KEY | Exercise M | 41.7K | $0 |
| Jun 1, 2026 | Frederick G Vogt KEY | Other F | 17.7K | $70.1K |
| Jun 1, 2026 | Frederick G Vogt KEY | Exercise M | 41.7K | $0 |
| Jun 1, 2026 | Raj K. Puri | Exercise M | 5.5K | $0 |
| Jun 1, 2026 | Raj K. Puri | Other F | 2.5K | $9.9K |
| Jun 1, 2026 | Raj K. Puri | Exercise M | 5.5K | $0 |
| Jun 1, 2026 | Finckenstein Friedrich Graf | Exercise M | 8.8K | $0 |
| Jun 1, 2026 | Finckenstein Friedrich Graf | Other F | 4.5K | $17.7K |
| Jun 1, 2026 | Finckenstein Friedrich Graf | Exercise M | 8.8K | $0 |
| Jun 1, 2026 | Igor Bilinsky | Exercise M | 8.8K | $0 |
| Jun 1, 2026 | Igor Bilinsky | Other F | 4.5K | $17.7K |
| Jun 1, 2026 | Igor Bilinsky | Exercise M | 8.8K | $0 |
| May 19, 2026 | Athena Countouriotis | Grant A | 10.5K | $0 |
| May 11, 2026 | Daniel Gordon Kirby | Exercise M | 10.0K | $0 |
| May 11, 2026 | Daniel Gordon Kirby | Other F | 2.4K | $9.0K |
| May 11, 2026 | Daniel Gordon Kirby | Exercise M | 10.0K | $0 |
| Mar 9, 2026 | Corleen M. Roche KEY | Grant A | 132.2K | $0 |
| Mar 9, 2026 | Frederick G Vogt KEY | Grant A | 235.0K | $0 |
| Mar 9, 2026 | Raj K. Puri | Grant A | 117.5K | $0 |
| Mar 9, 2026 | Daniel Gordon Kirby | Grant A | 132.2K | $0 |
| Mar 9, 2026 | Finckenstein Friedrich Graf | Grant A | 58.8K | $0 |
| Mar 9, 2026 | Igor Bilinsky | Grant A | 117.5K | $0 |
| Mar 8, 2026 | Iain D. Dukes KEY | Grant A | 231.3K | $0 |
| Mar 5, 2026 | Frederick G Vogt KEY | Exercise M | 62.5K | $0 |
| Mar 5, 2026 | Frederick G Vogt KEY | Other F | 26.8K | $122.5K |
| Mar 5, 2026 | Frederick G Vogt KEY | Exercise M | 62.5K | $0 |
| Mar 5, 2026 | Raj K. Puri | Exercise M | 39.1K | $0 |
| Mar 5, 2026 | Raj K. Puri | Other F | 18.4K | $84.1K |
| Mar 5, 2026 | Raj K. Puri | Exercise M | 39.1K | $0 |
| Mar 5, 2026 | Finckenstein Friedrich Graf | Exercise M | 31.2K | $0 |
| Mar 5, 2026 | Finckenstein Friedrich Graf | Other F | 16.5K | $75.7K |
| Mar 5, 2026 | Finckenstein Friedrich Graf | Exercise M | 31.2K | $0 |
| Mar 5, 2026 | Igor Bilinsky | Exercise M | 31.2K | $0 |
| Mar 5, 2026 | Igor Bilinsky | Other F | 16.6K | $76.2K |
| Mar 5, 2026 | Igor Bilinsky | Exercise M | 31.2K | $0 |
| Mar 2, 2026 | Frederick G Vogt KEY | Exercise M | 10.4K | $0 |
| Mar 2, 2026 | Frederick G Vogt KEY | Exercise M | 41.7K | $0 |
| Mar 2, 2026 | Frederick G Vogt KEY | Other F | 22.8K | $86.4K |
| Mar 2, 2026 | Frederick G Vogt KEY | Exercise M | 52.1K | $0 |
| Mar 2, 2026 | Raj K. Puri | Exercise M | 5.5K | $0 |
| Mar 2, 2026 | Raj K. Puri | Other F | 2.8K | $10.6K |
| Mar 2, 2026 | Raj K. Puri | Exercise M | 5.5K | $0 |
| Mar 2, 2026 | Finckenstein Friedrich Graf | Exercise M | 3.9K | $0 |
| Mar 2, 2026 | Finckenstein Friedrich Graf | Exercise M | 8.8K | $0 |
| Mar 2, 2026 | Finckenstein Friedrich Graf | Other F | 7.1K | $27.0K |
| Mar 2, 2026 | Finckenstein Friedrich Graf | Exercise M | 12.7K | $0 |
| Mar 2, 2026 | Igor Bilinsky | Exercise M | 3.5K | $0 |
| Mar 2, 2026 | Igor Bilinsky | Exercise M | 8.8K | $0 |
| Mar 2, 2026 | Igor Bilinsky | Other F | 6.9K | $26.2K |
| Mar 2, 2026 | Igor Bilinsky | Exercise M | 12.3K | $0 |
| Feb 24, 2026 | Daniel Gordon Kirby | Exercise M | 150.0K | $0 |
| Feb 24, 2026 | Daniel Gordon Kirby | Other F | 34.2K | $129.1K |
| Feb 24, 2026 | Daniel Gordon Kirby | Exercise M | 120.0K | $0 |
| Feb 10, 2026 | Daniel Gordon Kirby | Exercise M | 40.0K | $0 |
| Feb 10, 2026 | Daniel Gordon Kirby | Other F | 16.4K | $42.8K |
| Feb 10, 2026 | Daniel Gordon Kirby | Exercise M | 40.0K | $0 |
About IOVA insider trading
This page tracks insider transactions for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.